Enzalutamide blows Bicalutamide out of the water in STRIVE trial at AUA15
New Orleans – in today’s plenary session at the 2015 annual meeting of the American Urological Association (Twitter: #AUA15), Dr Celestia Higano (Seattle), presented the results of the STRIVE trial (NCT01664923) – a multicenter phase 2 study of enzalutamide (Xtandi) versus bicalutamide in men with nonmetastatic (M0) or metastatic castration-resistant prostate cancer (M1). These were men who were asymptomatic or mildly symptomatic.
Dr Higano noted that this was a very late breaking abstract; topline results were only announced a little over a month ago on April 2.
The TERRAIN trial also compared the efficacy of enzalutamide head-to-head against bicalutamide. We’ve updated our EAU 2015 TERRAIN post with the additional data presented here at AUA 2015 in New Orleans.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
